Novartis Ag

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

Harald Hach

Ulrich Westedt

Martin Knobloch

Norbert Steiger

Joerg Breitenbach

Joerg Rosenberg

Yi Gao

Jörg Breitenbach

Jörg Rosenberg

Ping Tong

Nancy E Sever

Ute Lander

Joerg Ogorka

Adivaraha Jayasankar

Marius Naris

Regina Reul

Colleen Garrett

Constanze Obermiller

Katrin Schneider

Michael Simon

Ralf Altenburger

Nicoletta Loggia

Jörg Ogorka

Benedikt Steitz

Samuel Kyeremateng

Katharina Asmus

Thomas Mueller

Donghua Zhu

Michael Siimon

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Solid pharmaceutical compositions for treating HCV

The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.

Melt-processed imatinib dosage form

A description is given of a process for the preparation of a pharmaceutical composition of a macrolide antibiotic in essentially noncrystalline form, in which the macrolide antibiotic, a water-swellable polymer and a proton donor are blended in an extruder in the presence of water and forced through a die, the ratio by weight of the sum of macrolide antibiotic, water-swellable polymer and proton donor to water being at least 1:1. The macrolide antibiotic is preferably clarithromycin and the water-swellable polymer is preferably chosen from crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose and crosslinked polyacrylic acid.

Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics

Growing community of inventors

Oberotterbach, Germany

Harald Hach